Effect of local interleukin-2 treatment on spontaneous tumours of different immunogenic strength

Cancer Immunology Immunotherapy

Volumn 47, Issue 6, 1999, Pages 307-314

  Fiszer Maliszewska, Lucja ^a   Den Otter, Willem ^b   Mordarski, Marian ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b Department of Functional Morphology ^*  (Netherlands)

Author keywords

Cancer immunotherapy; Immunogenicity; Interleukin 2; Spontaneous tumours

Indexed keywords

INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; IMMUNOGENICITY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-2; LUNG NEOPLASMS; LYMPHOMA; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PAPILLOMA; RECOMBINANT PROTEINS; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033029358     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050535     Document Type: Article

References (45)

1. Bailey DW (1982) How pure are inbred strains of mice? Immunol Today 3:210
2. Boon T, De Plaen E, Lurquin C, Van Den Eynde B, Van Der Bruggen P, Traversari C, Amar-Costesec A (1992) Identification of tumour rejection antigens recognized by T lymphocytes. Cancer Surv 13:23
3. Culver KW, Vickers TM, Lamsam JL, Walling HW, Seregina T (1995) Gene therapy for solid tumours. Br Med Bull 51:192
4. De Mik HJI, Koten JW, Maas RA, Dullens HFJ, Den Otter W (1991) Tumour regression by IL-2 mediated stagnation of blood flow. In Vivo 5:679
5. Den Otter W, Maas RA, Koten JW, Dullens HFJ, Bernsen M, Klein WR, Rutten VPMG, Steerenberg RA, Balemans L, Ruitenberg EJ, Hill FWG, Heintz APM (1991) Effective immunotherapy with local low doses of interleukin-2. In Vivo 5:561
6. De Weger RA, Wilbrink B, Moberts RMP, Mans D, Oskam R, Den Otter W (1987) Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice. Cancer Immunol Immunother 24:25
7. Dullens HFJ, Schakenraad S, Oostdijk A, Vuist W, Van Der Maas M, Den Otter W (1986) Specific tumouricidal activity of cytostatic macrophages and cytotoxic lymphocytes. Cancer Immunol Immunother 22:100
8. Everse LA, Bernsen MR, Dullens HFJ, Den Otter W (1996) The success of locoregional, low-dose recombinant interleukin-2 (rIL-2) therapy in tumor-bearing mice is dependent on the time of rIL-2 administration. J Exp Ther Oncol 1:231
9. Everse LA, Bernsen MR, Dullens HFJ, Den Otter W (1997) Priming of the antitumor response promotes efficacy of interleukin-2 therapy. Cancer Immunol Immunother 44:221
10. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumour cells bypasses T helper function in the generation of an anti-tumor response. Cell 60:397
11. Fiszer-Maliszewska L, Mordarski M, Madej JA (1993) Therapeutic potential of biological response modifiers against transplantable mouse tumours of spontaneous origin. I. Characterization of biological properties of tumour lines and preliminary data on response to cytostatic drugs and biomodulators. Arch Immunol Ther Exp 41:1
12. Forni G, Giovarelli M, Santoni A, Modesti A, Forni M (1986) Tumour inhibition by interleukin-2 at the tumour host interface. Biochim Biophys Acta 865:307
13. Graff RJ, Valeriote F, Medoff G (1975) Marked histo-incompatibility between and within sublines of AKR mice used in a syngeneic leukemia model. J Natl Cancer Inst 55:1015
14. Heaton KM, Grimm EA (1993) Cytokine combinations in immunotherapy for solid tumours: a review. Cancer Immunol Immunother 37:213
15. Herrmann F (1995) Cancer gene therapy: principles, problems, and perspectives. J Mol Med 73:157
16. Hewitt HB (1978) The choice of animal tumours for experimental studies of cancer therapy. Adv Cancer Res 27:149
17. Hewitt HB (1982) Animal tumour models and their relevance to human tumour immunology. J Biol Response Mod 1:107
18. Kallman RF, Brown JM, Denekamp J, Hill RP, Kummermehr J (1985) The use of rodent tumours in experimental cancer therapy: conclusions and recommendations from an international workshop. Cancer Res 45:6541
19. Kedar E, Klein E (1992) Cancer immunotherapy: are the results discouraging? Can they be improved? Adv Cancer Res 59:245
20. Klein G (1980) Immune and non-immune control of neoplastic development: contrasting effects of host and tumour evolution. Cancer 45:2486
21. Li Y, Hellström KE, Newby SA, Chen L (1996) Costimulation by DC48 and B7-1 induces immunity against poorly immunogenic tumours. J Exp Med 183:639
22. Maas RA, Dullens HFJ, De Jong WH, Den Otter W (1989) Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. Cancer Res 49:7037
23. Maas RA, Dullens HFJ, Den Otter W (1991) Mechanisms of tumor regression induced by low doses of interleukin-2. In Vivo 5:637
24. Maas RA, Van Weering DHJ, Dullens HFJ, Den Otter W (1991) Intratumoural low-dose interleukin-2 induces rejection of distant solid tumour. Cancer Immunol Immunother 33:389
25. + infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumour bearing mice. Immunobiology 188:281
26. Maas RA, Dullens HFJ, Van Weering DHJ, De Mik HJI, Koten JW, Belger RJ, Den Otter W (1993) Histological analysis of IL-2 induced regression of murine solid SL2 tumours. Biotherapy 6:83
27. Marincola FM, Venzon D, White D, Rubin JT, Lotze MT, Simonis TB, Balkissoon J, Rosenberg SA, Parkinson DR (1992) HLA association with response and toxicity in melanoma patients treated with interleukin 2-based therapy. Cancer Res 52:6561
28. McBride WH, Economou JS, Syljuasen RG, Parrish C, Hackman D, Latham V, Chiang CS, Dougherty GJ (1996) The effects of cytokine gene transfer into tumors on host cell infiltration and regression. Anticancer Res 16:1139
29. Ootsu K, Gotoh K, Houkan T (1989) Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumours. Cancer Immunol Immunother 30:71
30. Osband ME, Ross S (1990) Problems in the investigational study and clinical use of cancer immunotherapy. Immunol Today 11:193
31. Papa MZ, Mule JJ, Rosenberg SA (1986) Anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumours of three distinct histological types. Cancer Res 46:4973
32. Parmiani G (1990) An explanation of the variable clinical response to interleukin-2 and LAK cells. Immunol Today 11:113
33. Reif AE (1982) Antigenicity of tumours: a comprehensive system of measurement. Methods Cancer Res 20:4
34. Reif AE (1986) Relationship of success in classical immunotherapy to the relative immunorejective strength of the tumour. J Natl Cancer Inst 77:899
35. Restifo NP, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquivel F, Rosenberg SA (1993) Molecular mechanisms used by tumours to escape immune recognition: Immunogene therapy and the cell biology of major histocompatibility complex class I. J Immunother 14:182
36. Schultz RM, Papamatheakis JD, Luetzeler J, Ruiz P, Chirigos MA (1977) Macrophage involvement in the protective effect of pyran copolymer against the Madison lung carcinoma. Cancer Res 37:358
37. Scott OCA (1991) Tumour transplantation and tumour immunity: a personal view. Cancer Res 51:757
38. Sun T, Kim TS, Waltz MR, Cohen EP (1995) Interteukin-2 secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumour-specific immune responses that prolong the lives of tumour-bearing mice. Cancer Gene Ther 2:183
39. Suzuki M, Kikuchi T, Takatsuki F, Hamuro J (1994) Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumours, and the role of CD8-positive T cells. Cancer Immunol Immunother 38:1
40. Talmadge JE, Chirigos MA (1985) Comparison of immunomodulatory and immunotherapeutic properties of biological response modifiers. Springer Semin Immunopathol 8:429
41. Talmadge JE, Herberman RB (1986) The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treatm Rep 70:171
42. Talmadge JE, Lenz BF, Klabansky R, Simon R, Riggs C, Guo S, Oldham RK, Fidler IJ (1986) Therapy of atttochthonous skin cancers in mice with intravenously injected liposomes containing muramyltripeptide. Cancer Res 46:1160
43. Vaage J (1988) Local interleukin-2 therapy of mouse mammary tumours of various immunogenicities. Cancer Res 48:2193
44. Wainberg MA, Margolese RG, Weiss DW (1977) Differential response of various substrains of inbred strain 2 guinea pigs to immunotherapy with the methanol extraction residue (MER) of BCG. Cancer Immunol Immunother 2:101
45. Weiss DW (1984) Reflections on tumour origin, immunogenicity, and immunotherapy. Cancer Immunol Immunother 18:1